Today, pork producers must do all they can to manage production efficiency and control disease in the finisher. “We want to see the slow-growing, sick pigs recover quickly and get to market,” says Darin Madson, DVM, who conducted on-farm trials designed to improve the number of finishing pigs that reach market.
Madson hand-selected any pig that lagged behind the rest. He then treated those tail-enders with Draxxin (tulathromycin), a long-acting anti-infective injectable solution from Pfizer Animal Health used to treat pigs breaking with swine influenza virus infections.
Those pigs also had or showed clinical signs of other infections, including porcine reproductive and respiratory syndrome, Haemophilus parasuis and Mycoplasma hyopneumoniae. Injections occurred during the first or second month of the finishing phase, depending on when the pigs started to exhibit disease symptoms.
Madson found that the lowest return on investment result was 3:1. His highest returning group came in at 8:1.
Grant Allison, DVM, with the Walcott Veterinary Clinic in Walcott, Iowa, saw similar results treating pigs that were smaller than the rest of their group. “We sorted and then treated pigs that were falling behind the group,” Allison says. “We found great success by using one shot of Draxxin right away to get those pigs the best chance of getting back on track,” Allison notes.
“These 40- to 60-pound pigs were worth at least $50 due to high feed costs. We felt they could reach market weight with the rest of the group if treated successfully.”
Draxxin is indicated against five key bacterial pathogens that cause swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis and Mycoplasma hyopneumoniae.
For more information about the proper use of Draxxin in swine operations, producers should talk to their veterinarian or visit www.draxxin.com. Always follow the pre-slaughter withdrawal time.